

G<sup>8</sup>  
Renaissance chemiluminescent reagent (DuPont NEN) and exposed to Kodak XAR-2 film. A commercially prepared filter containing poly(A)<sup>+</sup> RNAs (3 µg each) from human heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas (Clontech) was hybridized with a radiolabelled fragment and processed as described above. Following autoradiography, the blot was stripped by washing in boiling 0.1xSSC, 0.1% SDS for 2x15 minutes at 65 °C and then probed as described above with a 1.4-kb cDNA fragment encoding human LPL. This fragment was obtained by RT-PCR of the THP-1 RNA (PMA and oxLDL treated) using the 5' LPL and 3' LPL primers 5'-ACCACCATGGAGAGCAAAGCCCTG-3' (SEQ ID NO: 24) and 5'-CCAGTTTCAGCCTGACTTCTTATTC-3' (SEQ ID NO: 25), respectively. After exposure to film, the membranes were stripped again and reprobed with a radiolabelled fragment of human β actin cDNA to normalize to RNA content.

In the Claims

G<sup>9</sup>  
20. (Amended three times) A composition for increasing the level of LIPG polypeptide in a patient comprising a pharmaceutically acceptable carrier and an LIPG polypeptide which: (A) binds heparin; (B) has homology with human lipoprotein lipase and hepatic lipase; (C) comprises a 39 kD catalytic domain of the triacylglycerol lipase family which contains serine at residue position 169, aspartate at residue position 193, and histidine at residue position 274; (D) comprises a 19-residue lid region which is characteristic of LIPG polypeptide; and (E) has lipase activity.

G<sup>10</sup>  
85. (Amended) An isolated LIPG polypeptide which: (A) binds heparin; (B) has homology with human lipoprotein lipase and hepatic lipase; (C) comprises a 39 kD catalytic domain of the triacylglycerol lipase family which contains serine at residue position 169, aspartate at residue position 193, and histidine at

G<sup>10</sup>

residue position 274; (D) comprises a 19-residue lid region which is characteristic of LIPG polypeptide; and (E) has lipase activity.

90. (Amended) The polypeptide of Claim 85, wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 8 and has an apparent molecular weight of about 55 kD on a 10% SDS-PAGE gel.

G<sup>11</sup>

91. (Amended) The polypeptide of Claim 85, wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 8 and has an apparent molecular weight of about 68 kD on a 10% SDS-PAGE gel.

Please add the following claims.

- 96. (New) An isolated polypeptide of Claim 85, wherein said isolated polypeptide is selected from the group consisting of: (A) a polypeptide which comprises an amino acid sequence of SEQ ID NO: 8; and (B) a polypeptide which comprises an amino acid sequence of SEQ ID NO: 6.

G<sup>12</sup>

97. (New) A composition according to Claim 20 wherein said polypeptide is selected from the group consisting of: (A) a polypeptide which comprises an amino acid sequence of SEQ ID NO: 8; and (B) a polypeptide which comprises an amino acid sequence of SEQ ID NO: 6.--

Please cancel Claims 66 to 70, 72, 77, and 92 without prejudice.

In the Abstract

Please replace the abstract with the following rewritten abstract.